Core Viewpoint - Yuyuan Pharmaceutical plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its competitiveness and international brand image, but faces significant challenges including declining financial performance and cash flow issues [1][5]. Financial Performance - Yuyuan Pharmaceutical's revenue and net profit have been declining annually from 2022 to 2024, with revenues of 45.21 billion, 41.83 billion, and 37.67 billion respectively, representing year-on-year declines of 8.53%, 7.61%, and 9.9% [2][8]. - The net profit for the same period was 3.35 billion, 1.85 billion, and 1.24 billion, with declines of 38.56%, 44.87%, and 33.05% respectively [2][8]. Core Product Challenges - The decline in performance is primarily due to issues with the core product, Ginkgo Biloba Extract Injection, which has faced compliance crises and industry downturns [2][9]. - The price of the core product was significantly reduced from 24.1 yuan to 11.2 yuan per unit, a drop of over 53%, impacting revenue and gross profit [2][9]. Market Trends - The market for traditional Chinese medicine injections has shrunk from nearly 900 billion in 2016 to approximately 443 billion in 2024, indicating a significant and ongoing decline [3][9]. Strategic Shift - In response to traditional business challenges, Yuyuan Pharmaceutical is shifting its focus to innovative drug development, particularly in nucleic acid drugs like siRNA and mRNA [3][10]. - The company's lead drug candidate, YKYY015, is still in Phase I clinical trials in China and has not yet started in the U.S., indicating a long path to commercialization [4][10]. Cash Flow and Debt - The company reported a 60.9% year-on-year decrease in net cash flow from operating activities for the first three quarters of 2025, with ongoing cash outflows from investment activities [4][10]. - As of the end of Q3 2025, the company's cash balance was approximately 1 billion, down from 1.33 billion at the end of 2024, while interest-bearing debt reached 662 million, with short-term repayment pressures increasing significantly [4][10]. Financing and Dividend Issues - Yuyuan Pharmaceutical is planning to raise up to 300 million through a private placement and is also pursuing H-share listing amid tight cash flow [5][11]. - Despite financial pressures, the company distributed dividends of 3.06 billion, 4.95 billion, and 889 million in 2022, 2023, and 2024, respectively, raising questions about the rationale behind such payouts during a critical transition period [6][11]. Project Delays - Several investment projects have been delayed, including the completion of the R&D center and various production lines, with new completion dates pushed to late 2025 and 2026 [11][12]. - The planned investment of 80 million in a smart coding system was terminated, with funds redirected to new drug development projects, highlighting uncertainties in project execution [12].

Core Viewpoint - Yuyuan Pharmaceutical (688658) has submitted an application for H-share listing on the Hong Kong Stock Exchange, marking a significant move following its 2020 debut on the STAR Market. This "A+H" strategy aims to broaden financing channels amid macro policy adjustments and pressure on core products due to regulatory price cuts [1]. Group 1: Core Product and Financial Performance - The company's core product, Ginkgo biloba extract injection (Yuyuan Tong), has historically supported its performance, holding approximately 94.1% market share in China. However, recent regulatory changes have exposed vulnerabilities in this concentrated product structure [2]. - In 2024, the National Healthcare Security Administration targeted the "one drug, two prices" phenomenon, leading to a price reduction of 38% to 53% for Yuyuan Tong. This adjustment resulted in a significant revenue decline, with a 41.20% year-on-year drop in revenue for the first nine months of 2025, totaling 1.759 billion yuan compared to 2.992 billion yuan in the same period last year [2]. - The company's net profit attributable to shareholders for the first three quarters of 2025 was -148 million yuan, a 170.56% decrease from 210 million yuan in the same period of 2024, indicating challenges in transitioning its core growth engine [2]. Group 2: Fundraising Efficiency and Project Management - The market is closely watching Yuyuan Pharmaceutical's management efficiency of previously raised funds, as the company raised approximately 2.018 billion yuan during its STAR Market IPO in 2020. However, the expected outcomes from these funds have not been fully realized, with project delays noted [3]. - By the end of 2024, the "R&D Center Construction" project had only achieved 69.28% of its planned investment progress, while the "High-end Pharmaceutical Formulation Industrialization Project" reached only 59.07%. Additionally, some projects have been postponed to 2025 or 2026 due to external environment changes [3]. Group 3: Cash Flow and R&D Investment - Yuyuan Pharmaceutical's cash flow is under pressure, with a net cash flow from operating activities of 170 million yuan for the first three quarters of 2025, down over 60% year-on-year. This decline is attributed to a significant drop in revenue, while fixed R&D expenditures and production costs have not decreased proportionately [5]. - Despite facing losses, the company has maintained its R&D investment, spending 329 million yuan in the first three quarters of 2025. It is advancing multiple cutting-edge technology platforms, including small nucleic acid drugs and mRNA vaccines, although competition in these areas is intense [6]. Group 4: Market Position and Future Outlook - Yuyuan Pharmaceutical's past compliance issues may increase the scrutiny of its H-share listing process. The company's ability to attract international institutional investors will depend on the quality of clinical data from its R&D pipeline by 2026 [7]. - The H-share listing represents a defensive expansion strategy, aiming to mitigate the impact of core product price cuts and secure funding for long-term, capital-intensive nucleic acid drug development. However, the shift in capital market logic from "expectations" to "certainty" poses challenges for the company [7].